eyeforpharma Barcelona 2018

eyeforpharma13 - 15 March 2018, Barcelona, Spain.
eyeforpharma Barcelona is an annual pilgrimage for pharma's executives who want to map their future commercial success. Now it has become the place to map a different journey, that of our customers and patients. Gain their trust and serve as their guiding light towards better outcomes for all.

One eyeforpharma Barcelona. 9 in-depth commercial pharma conferences on the key issues of 2018 and beyond. This year we will bring you unrivalled expertise, patient insights, real-world data - the building blocks to deliver innovative and complete healthcare solutions, to make a real difference to the lives of patients and customers.

1. A Vision for the Future
2. Commercial Model Innovation
3. Talent and Diversity
4. Patient Partnerships
5. Advances in Customer Engagement
6. Digital Innovation and Analytics
7. Sales Force Effectiveness
8. Interactive Sessions - you lead the discussion
9. Medical Affairs

Why you can't miss Barcelona 2018

Barcelona is not a normal conference. Our mission is to create the mass movement we need across the pharma industry.

We must ask ourselves is it possible for a pharma company to be a credible, go-to source of health knowledge? Is it possible to be trusted, respected and admired? Despite having all the resources, expertise and reach, pharmaceutical companies are still a long way from this. To get there, each company must better appreciate the value it provides - and to have a greater vision for the value it can provide.

2018 will guarantee:

  • Collaborative setting: Our aim to ensure your key stakeholder are present to advance partnerships with healthcare, technology, patient and patient association
  • An Inspiring Agenda: As you undergo a commercial evolution we will cover 9 themes, provide intimate workshops and keynote sessions to help direct your journey
  • 1200+ in attendance: If you are looking for one commercial meeting to attend in 2018, Barcelona will be sure to give you the most senior networking opportunities possible
  • NO Sales Pitch: this is an independently researched event committed to equipping you with the techniques and expertise to drive your business. You will take-away actionable insights proven to drive your commercial strategy
  • More Than 80 Executive-level Thought Leaders sharing their experience and knowledge. Take this opportunity to transform your organisation, become truly customer-centric and improve healthcare outcomes.

Join the most forward-thinking speakers from across Europe including C-Level, VPs and Industry leaders from J&J, Bayer Pharmaceuticals, Lilly Bio Medicines, Teva, Takeda and MSD. This is the ideal place to ensure your commercial strategy is prepared for 2018 and beyond.

World Pharma News readers can benefit from an exclusive discount - save €200 using the unique discount code WPN200 when you register online here.

For further information, please visit:
http://www.eyeforpharma.com/barcelona/

About eyeforpharma
Our mission is to make pharma more open and valued. The ultimate driver for the pharmaceutical industry's health is meeting the needs of patients, otherwise it will cease to matter. For healthcare to be as good as it could be, the strength, skills and resources of our industry need to be fully integrated into health outcomes and we need pharma experience at the decision-making table. We believe the industry must focus on a business model combining service with product, with patients at the centre.

Most Popular Now

Sanofi and GSK sign agreements with the Government…

Sanofi and GSK have signed agreements with the Government of Canada for the supply of up to 72 million doses of an adjuvanted COVID-19 vaccine, beginning in 2021. Thom...

BioNTech and Pfizer initiate rolling submission to…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the initiation of a rolling submission to the European Medicines Agency (EMA) for BNT162b2, the lea...

Johnson & Johnson initiates pivotal global Pha…

Johnson & Johnson (NYSE: JNJ) (the Company) announced the launch of its large-scale, pivotal, multi-country Phase 3 trial (ENSEMBLE) for its COVID-19 vaccine candidate, J...

Scientists trace severe COVID-19 to faulty genes a…

More than 10 percent of young and healthy people who develop severe COVID-19 have misguided antibodies that attack not the virus, but the immune system itself, new resear...

Vir Biotechnology and GSK announce global expansio…

Vir Biotechnology, Inc. (Nasdaq: VIR) and GlaxoSmithKline plc (LSE/NYSE: GSK) announced the global expansion to Phase 3 of the COMET-ICE (COVID-19 Monoclonal antibody Eff...

Johnson & Johnson announces European Commissio…

Johnson & Johnson (NYSE: JNJ) (the Company) announced the European Commission (EC), acting on behalf of the European Union (EU) Member States, has approved an Advance Pur...

Johns Hopkins researchers publish COVID-19 'predic…

Using a combination of demographic and clinical data gathered from seven weeks of COVID-19 patient care early in the coronavirus pandemic, Johns Hopkins researchers today...

Web resources bring new insight into COVID-19

Researchers around the world are a step closer to a better understanding of the intricacies of COVID-19 thanks to two new web resources developed by investigators at Bayl...

COVID-19 vaccine AZD1222 clinical trial resumed in…

The Phase I/II clinical trial for the COVID-19 vaccine AZD1222 has resumed in Japan after discussion with the Japanese Pharmaceuticals and Medical Devices Agency (PMDA). ...

COVID-19 Long-Acting AntiBody (LAAB) combination A…

AstraZeneca's long-acting antibody (LAAB) combination, AZD7442, will advance into two Phase III clinical trials in more than 6,000 participants at sites in and outside th...

Adequate levels of vitamin D reduces complications…

Hospitalized COVID-19 patients who were vitamin D sufficient, with a blood level of 25-hydroxyvitamin D of at least 30 ng/mL (a measure of vitamin D status), had a signif...

Protective antibodies persist for months in surviv…

People who survive serious COVID-19 infections have long-lasting immune responses against the virus, according to a new study led by researchers at Massachusetts General ...